Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | 0.00% | +17.95% | +109.09% |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.19M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.3M | Net income 2023 | -2M -1.3M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 720K | Net cash position 2023 | 401K 262K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.35% |
1 week | +17.95% | ||
Current month | +17.95% | ||
1 month | +6.98% | ||
3 months | +119.05% | ||
6 months | +43.75% | ||
Current year | +109.09% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.046 | 0.00% | 20 000 |
24-04-24 | 0.046 | +6.98% | 111,942 |
24-04-23 | 0.043 | +2.38% | 22,046 |
24-04-22 | 0.042 | +7.69% | 1,130,501 |
24-04-19 | 0.039 | -7.14% | 510,000 |
Delayed Quote Australian S.E., April 25, 2024 at 10:23 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+109.09% | 5.01M | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B |
- Stock Market
- Equities
- ANR Stock